Author(s):
Christophorus Oetama Adiatmaja, Jusak Nugraha, Arie Utariani
Email(s):
jusak.nugraha@yahoo.comQ
DOI:
10.52711/0974-360X.2022.00798 
Address:
Christophorus Oetama Adiatmaja1, Jusak Nugraha1*, Arie Utariani2
1Clinical Pathology Department, Faculty of Medicine - Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya, Indonesia.
2Anesthesiology and Intensive Therapy Department, Faculty of Medicine - Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya, Indonesia.
*Corresponding Author
Published In:
Volume - 15,
Issue - 10,
Year - 2022
ABSTRACT:
This cross-sectional study was conducted from June 2020 to May 2021. This study recruited 86 patients with confirmed PCR positive for COVID-19 who were treated in the isolation ward of Dr. Soetomo Teaching Hospital, Surabaya, Indonesia. Examination of serum levels of IL-6, CRP, and LDH was performed on the first and the sixth day of hospital admission. Found on the first day of admission the same significant correlation between IL-6 and CRP on males and females with rs=0,475 (p<0,01) and rs=0,663 (p<0,01) respectively. Correlation between IL-6 and LDH on the first day of admission on both males and females were also significant with rs=0,403 (p<0,01) and rs=0,484 (p<0,01) respectively. IL-6 and CRP on the sixth day of admission showed significant correlation on males with rs=0,621 (p<0,01), but not on females with rs=0,120 (p=0,586). IL-6 and LDH on the sixth day of admission also showed significant correlation on males with rs=0,544 (p<0,01), but not on females with rs=0,030 (p=0,893). In conclusion, there were significant positive correlations between IL-6, CRP, and LDH on the first day of admission on both male and female subjects which showed that IL-6 was associated with inflammatory response on the acute phase of COVID-19. However, on the sixth day of admission, IL-6 showed significant positive correlations with CRP and LDH only on male subjects, but not on female subjects.
Cite this article:
Christophorus Oetama Adiatmaja, Jusak Nugraha, Arie Utariani. Correlation between Interleukin-6, CRP, and LDH in COVID-19 patients of Dr. Soetomo Teaching Hospital, Surabaya, Indonesia. Research Journal of Pharmacy and Technology 2022; 15(10):4753-7. doi: 10.52711/0974-360X.2022.00798
Cite(Electronic):
Christophorus Oetama Adiatmaja, Jusak Nugraha, Arie Utariani. Correlation between Interleukin-6, CRP, and LDH in COVID-19 patients of Dr. Soetomo Teaching Hospital, Surabaya, Indonesia. Research Journal of Pharmacy and Technology 2022; 15(10):4753-7. doi: 10.52711/0974-360X.2022.00798 Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-10-71
REFERENCES:
1. Ansori ANM, Kharisma VD, Fadholly A, Tacharina MR, Antonius Y, Parikesit AA. Severe acute respiratory syndrome coronavirus-2 emergence and its treatment with alternative medicines: A review. Res J Pharm Tech. 2021; 14(10).
2. Ansori ANM, Kharisma VD, Muttaqin SS, Antonius Y, Parikesit AA. Genetic variant of SARS-CoV-2 isolates in Indonesia: Spike glycoprotein gene. Journal of Pure Applied Microbiology. 2020; 14: 971-978.
3. Atul Sharma, Keerthi Mohanan. Obstacles Faced by Nurses working in Covid-19 Unit: A Developing Country view Point. Asian J. Nursing Education and Research. 2020; 10(4):459-462. doi: 10.5958/2349-2996.2020.00098.1
4. Sakshi Nand, Neelabh. Therapeutic effect of certain Indian medicinal compounds against the Corona Virus: An in-silico study. Asian Journal of Pharmaceutical Research. 2021; 11(3):167-2. doi: 10.52711/2231-5691.2021.00031
5. Dhanashri Aware, Sachin Rohane. A Role of Herbal Drug as an Immunity Booster during Covid-19 Pandemic. Asian Journal of Pharmaceutical Research. 2021; 11(3):206-1. doi: 10.52711/2231-5691.2021.00037
6. Ali Adel Dawood. Using Remdesivir and Dexamethasone for Treatment of SARS-CoV-2 Shortens the patient's stay in the Hospital. Asian Journal of Pharmaceutical Research. 2021; 11(2):138-0. doi: 10.52711/2231-5691.2021.00026
7. Manisha Rokade, Pradnya Khandagale. Coronavirus Disease: A Review of a New Threat to Public Health. Asian J. Pharm. Res. 2020; 10(3):241-244. doi: 10.5958/2231-5691.2020.00042.8
8. Manisha Rokade, Pradnya Khandagale. Coronavirus Disease: A Review of a New Threat to Public Health. Asian J. Pharm. Res. 2020; 10(3):241-244. doi: 10.5958/2231-5691.2020.00042.8
9. B. V. Naresh. A Review of the 2019 Novel Coronavirus (COVID-19) Pandemic. Asian J. Pharm. Res. 2020; 10(3):233-238. doi: 10.5958/2231-5691.2020.00040.4
10. Niloy Sarkar, Bijoy Kumar Mandal, Soumya Paul. Activity, Effect on Human and Salvation from effect of COVID-19. Asian Journal of Management. 2021; 12(2):228-4. doi: 10.52711/2321-5763.2021.00035
11. Darshana Kumari Wankhede. COVID-19- Problem faced by Indians during Lockdown. Asian J. Nursing Education and Research. 2020; 10(4):501-504. doi: 10.5958/2349-2996.2020.00108.1
12. Kharisma VD and Ansori ANM. Construction of epitope-based peptide vaccine against SARS-CoV-2: Immunoinformatics study. Journal of Pure Applied Microbiology. 2020; 14(suppl 1): 999-1005.
13. Fahmi M, Kharisma VD, Ansori ANM, Ito M. Retrieval and investigation of data on SARS-CoV-2 and COVID-19 using bioinformatics approach. Adv Exp Med Biol. 2021; 1318: 839-857. doi: 10.1007/978-3-030-63761-3_47.
14. Prathmesh L. Jarag, Manohar D. Kengar, Ravina R. Jadhav, Aishwarya S. Shinde, Shweta S. Koli, P. P. Honmane. On overview- Corona virus and Hanta virus Disease. Asian J. Res. Pharm. Sci. 2020; 10(3):178-182. doi: 10.5958/2231-5659.2020.00034.X
15. Kharisma VD, Aghata A, Ansori ANM, Widyananda MH, Rizky WC, Dings TGA, Derkho M, Lysakova I, Antonius Y, Rosadi I, Zainul R. Herbal combination from Moringa oleifera Lam. and Curcuma longa L. as SARS-CoV-2 antiviral via dual inhibitor pathway: A viroinformatics approach. J Pharm Pharmacogn Res. 2022; 10(1): 138–146.
16. Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al. C-reactive protein and clinical outcomes in patients with COVID-19. European Heart Journal. 2021 Jun 14;42(23):2270–9. doi: 10.1093/eurheartj/ehaa1103.
17. Gong J, Dong H, Xia SQ, Huang YZ, Wang D, Zhao Y, et al. Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia. medRxiv. 2020;2020.02.25.20025643.
18. Luo X, Zhou W, Yan X, Guo T, Wang B, Xia H, et al. Prognostic value of C-reactive protein in patients with COVID-19. medRxiv. 2020;2020.03.21.20040360.
19. Drent M, Cobben NAM, Henderson RF, Wouters EFM, van Dieijen-Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. European Respiratory Journal. 1996 Aug 1;9(8):1736–42. doi: 10.1183/09031936.96.09081736.
20. Valvona CJ, Fillmore HL, Nunn PB, Pilkington GJ. The Regulation and Function of Lactate Dehydrogenase A: Therapeutic Potential in Brain Tumor. Brain Pathology. 2016 Jan;26(1):3–17. doi: 10.1111/bpa.12299.
21. Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. The American Journal of Emergency Medicine. 2020. DOI: 10.1016/j.ajem.2020.05.073
22. Martha JW, Wibowo A, Pranata R. Prognostic value of elevated lactate dehydrogenase in patients with COVID-19: A systematic review and meta-analysis. Postgraduate Medical Journal. 2021. Doi: postgradmedj-2020-139542. doi: 10.1136/postgradmedj-2020-139542.
23. BD. BDTM Cytometric Bead Array (CBA) Human Th1/Th2/Th17 Cytokine Kit Instruction Manual. 2019.
24. Dimension Clinical Chemistry System Instruction Manual. 2008.
25. Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nature Communications. 2020 Dec 9;11(1):6317. doi: 10.1038/s41467-020-19741-6.
26. Mukherjee S, Pahan K. Is COVID-19 Gender-sensitive? Journal of Neuroimmune Pharmacology. 2021 Mar 6;16(1):38–47. doi: 10.1007/s11481-020-09974-z.
27. Turista DDR, Islamy A, Kharisma VD, Ansori ANM. Distribution of COVID-19 and phylogenetic tree construction of SARS-CoV-2 in Indonesia. J Pure Appl Microbiol. 2020; 14: 1035-1042.
28. Marik PE, DePerrior SE, Ahmad Q, Dodani S. Gender‐based disparities in COVID-19 patient outcomes. Journal of Investigative Medicine. 2021 Apr;69(4):814–8. doi: 10.1136/jim-2020-001641.
29. Vahidy FS, Pan AP, Ahnstedt H, Munshi Y, Choi HA, Tiruneh Y, et al. Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: Cross-sectional analysis from a diverse US metropolitan area. Lazzeri C, editor. PLOS ONE. 2021 Jan 13;16(1):e0245556. doi: 10.1371/journal.pone.0245556.
30. Santa Cruz A, Mendes-Frias A, Oliveira AI, Dias L, Matos AR, Carvalho A, et al. Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia. Frontiers in Immunology. 2021 Feb 18;12. doi: 10.3389/fimmu.2021.613422
31. Magro G. SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? SGP130Fc. Cytokine: X. 2020 Jun;2(2):100029. doi: 10.1016/j.cytox.2020.100029.
32. Ansori ANM, Kusala MKJ, Normalina I, Indrasari S, Alamudi MY, Nidom RV, Santoso KP, Rachmawati K, Nidom CA. Immunoinformatic investigation of three structural protein genes in Indonesian SARS-CoV-2 isolates. Sys Rev Pharm. 2020; 11(7): 422-434.